Corcept Therapeutics Incorporated (CORT)

Working capital turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 675,040 628,555 569,610 523,529 482,375 450,026 428,153 413,824 401,858 397,624 392,027 380,229 365,978 352,891 343,087 340,064 353,874 356,034 351,212 334,904
Total current assets US$ in thousands 471,602 466,978 560,846 503,367 458,636 431,527 432,588 528,179 498,707 452,402 427,555 388,220 381,387 401,900 411,270 409,624 524,247 463,493 438,333 391,836
Total current liabilities US$ in thousands 140,773 126,216 100,750 97,202 104,505 121,873 93,059 25,216 81,588 53,068 54,038 57,244 6,908 44,757 45,402 40,601 10,554 43,048 42,243 36,005
Working capital turnover 2.04 1.84 1.24 1.29 1.36 1.45 1.26 0.82 0.96 1.00 1.05 1.15 0.98 0.99 0.94 0.92 0.69 0.85 0.89 0.94

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $675,040K ÷ ($471,602K – $140,773K)
= 2.04

Corcept Therapeutics Incorporated's working capital turnover has demonstrated fluctuations over the analyzed periods, based on the provided data. The ratio has varied between 0.69 and 2.04, indicating changes in the efficiency with which the company has been able to utilize its working capital to generate revenue.

In the initial periods, from December 2020 to March 2022, the working capital turnover remained relatively stable around the range of 0.69 to 1.15. From June 2022 onwards, there was an upward trend observed, with the ratio reaching a peak of 2.04 by December 31, 2024.

A working capital turnover ratio greater than 1 suggests that the company is effectively using its working capital to generate sales. The significant increase in the ratio from September 2024 to December 2024 may indicate improved efficiency in managing working capital or an increase in sales relative to the working capital invested.

Overall, the analysis of Corcept Therapeutics Incorporated's working capital turnover indicates varying levels of efficiency in utilizing working capital over time, with a notable improvement in recent periods. This suggests potential enhancements in the company's operational performance and financial management.